Atlas Venture Life Science Advisors, LLC - Q1 2023 holdings

$739 Million is the total value of Atlas Venture Life Science Advisors, LLC's 16 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 0.0% .

 Value Shares↓ Weighting
DYN BuyDyne Therapeutics, Inc.$113,880,372
-0.4%
9,885,449
+0.2%
15.42%
+11.9%
DAWN BuyDay One Biopharmaceuticals, Inc.$101,724,228
-37.5%
7,608,394
+0.5%
13.77%
-29.8%
AVTE BuyAerovate Therapeutics, Inc.$41,131,652
-30.4%
2,039,249
+1.1%
5.57%
-21.8%
GBIO BuyGeneration Bio, Co.$35,601,781
+9.4%
8,279,484
+0.0%
4.82%
+23.0%
AVRO BuyAvroBio, Inc.$4,541,381
+40.9%
4,541,381
+0.5%
0.62%
+58.5%
MGTA BuyMagenta Therapeutics, Inc.$3,013,262
+119.4%
3,791,698
+9.1%
0.41%
+147.3%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2023-05-15
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
Kymera Therapeutics, Inc.8Q3 202340.1%
Day One Biopharmaceuticals, Inc.8Q3 202326.8%
Dyne Therapeutics, Inc.8Q3 202315.4%
Replimune Group, Inc.8Q3 20239.4%
Generation Bio, Co.8Q3 20239.1%
Aerovate Therapeutics, Inc.8Q3 20237.2%
Akero Therapeutics, Inc.8Q3 20234.3%
Ikena Oncology, Inc.8Q3 20235.8%
Xilio Therapeutics, Inc.8Q3 20234.1%
AVROBIO INC8Q3 20231.6%

View Atlas Venture Life Science Advisors, LLC's complete holdings history.

Latest filings
TypeFiled
13F-HR2024-02-09
13F-HR2023-11-13
13F-HR2023-08-11
13F-HR2023-05-15
13F-HR2023-02-14
13F-HR2022-11-09
13F-HR2022-08-03
13F-HR2022-05-16
13F-HR2022-05-16

View Atlas Venture Life Science Advisors, LLC's complete filings history.

Export Atlas Venture Life Science Advisors, LLC's holdings